Arrowhead Pharmaceuticals Inc.’s filing revealed that its Chief Discovery/Trans Medicine Hamilton James C unloaded Company’s shares for reported $0.17 million on Apr 01 ’24. In the deal valued at $28.03 per share,6,000 shares were sold. As a result of this transaction, Hamilton James C now holds 204,851 shares worth roughly $4.92 million.
Then, Lu Hongbo bought 1,000 shares, generating $27,500 in total proceeds. Upon buying the shares at $27.50, the Director now owns 33,680 shares.
Before that, Lu Hongbo bought 1,000 shares. Arrowhead Pharmaceuticals Inc. shares valued at $28,000 were divested by the Director at a price of $28.00 per share. As a result of the transaction, Lu Hongbo now holds 32,680 shares, worth roughly $0.78 million.
BofA Securities initiated its Arrowhead Pharmaceuticals Inc. [ARWR] rating to a Buy in a research note published on December 04, 2023; the price target was $29. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid September with a ‘”a Neutral”‘ rating. TD Cowen began covering ARWR with “an Outperform” recommendation on July 21, 2023. SVB Securities revised its rating on May 12, 2023. It rated ARWR as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of ARWR
On Monday, Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] saw its stock fall -2.79% to $24.01. Over the last five days, the stock has lost -6.58%. Arrowhead Pharmaceuticals Inc. shares have fallen nearly -21.54% since the year began. Nevertheless, the stocks have fallen -21.28% over the past one year. While a 52-week high of $42.48 was reached on 01/10/24, a 52-week low of $20.67 was recorded on 04/15/24. SMA at 50 days reached $29.55, while 200 days put it at $29.55. A total of 0.88 million shares were traded, compared to the trading of 0.71 million shares in the previous session.
Levels Of Support And Resistance For ARWR Stock
The 24-hour chart illustrates a support level at 23.55, which if violated will result in even more drops to 23.10. On the upside, there is a resistance level at 24.66. A further resistance level may holdings at 25.32. The Relative Strength Index (RSI) on the 14-day chart is 31.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.12%. Stochastics %K at 10.08% indicates the stock is a buying.
The most recent change occurred on April 26, 2023 when SMBC Nikko began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
